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Abstract: Probiotics are beneficial microbes that confer a realistic health benefit on the 
host, which in combination with prebiotics, (indigestible dietary fibre/carbohydrate), also 
confer a health benefit on the host via products resulting from anaerobic fermentation. 
There is a growing body of evidence documenting the immune-modulatory ability of 
probiotic bacteria, it is therefore reasonable to suggest that this is potentiated via a 
combination of prebiotics and probiotics as a symbiotic mix. The need for probiotic 
formulations has been appreciated for the health benefits in “topping up your good 
bacteria” or indeed in an attempt to normalise the dysbiotic microbiota associated with 
immunopathology. This review will focus on the immunomodulatory role of probiotics and 
prebiotics on the cells, molecules and immune responses in the gut mucosae, from 
epithelial barrier to priming of adaptive responses by antigen presenting cells: immune fate 
decision—tolerance or activation? Modulation of normal homeostatic mechanisms, 
coupled with findings from probiotic and prebiotic delivery in pathological studies, will 
highlight the role for these xenobiotics in dysbiosis associated with immunopathology in 
the context of inflammatory bowel disease, colorectal cancer and hypersensitivity. 
Keywords: probiotics; prebiotics; synbiotics; immunomodulation; tolerance; activation; 
cytokines; inflammatory bowel disease; cancer; hypersensitivity 
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1. Introduction 
The regular intake of beneficial microorganisms, or probiotics, is an extensively-studied approach 
for tapping into the health benefits bestowed by commensal microorganisms colonising the 
gastrointestinal tract (GIT) of the healthy human host. The probiotic strains used for human 
consumption must be of human origin, non-pathogenic and survive gastrointestinal transit in order to 
confer health benefits on the host [1]. Owing to their non-pathogenic profile Lactobacilli and 
bifidobacteria are the most commonly used species and significantly influence human health through a 
range of effects which include; detoxification of xenobiotics [2], biosynthesis of vitamin K [3], 
metabolic effects of fermentation of indigestible dietary fibre [4], positive influence on transit of 
luminal contents by peristalsis [5], competition with pathogenic microbes for nutrients and binding 
sites on mucosal epithelial cells [6] and modulation of the host’s immune response [7]. 
Non-pathogenic bacteria such as probiotic strains of Escherichia coli have been demonstrated to 
exclude pathogens by suppressing pathogenic growth through the secretion of potent antimicrobial 
peptides (AMPs) such as the bacteriocin, microsin S [8]. Moreover, co-administration with prebiotics 
(synbiotics) may work in cooperation to selectively promote the growth and activity of one or more 
beneficial probiotic species [9,10]. Ingestion of prebiotics alone can stimulate the activity of  
pre-existing indigenous species which have the potential to be a more cost-effective strategy in 
positively modifying pre-exisiting commensal microflora [11,12]. Prebiotics are defined as natural or 
processed ‘functional foods’ which contain biologically active compounds that have documented 
clinical benefits on health, ranging from prevention of colorectal cancer to modulation of host defences 
to viral and bacterial infections by altering the interactions between pathogenic and beneficial  
bacteria [9,13]. The most extensively studied prebiotics are the fructans (inulin, fructo-oligosacharides 
(FOS)) and galacto-oligosaccharides (GOS) which, owing to their chemical structure, are indigestable 
in the small intestine and are anaerobically fermented by bacteria in the colon [14,15]. This 
fermentation of non-digestible dietary fibre/carbohydrate results in the production of short chain fatty 
acids, (SCFAs—acetate, proprionate, butyrate), that have significant positive impacts on intestinal 
epithelial cell function, including maintenance of metabolism, proliferation, differentiation and 
promotion a low pH5 of the gut environment, favouring beneficial microbes with a concomitant 
reduction in pathogen bacterial growth and viability [16,17].  
2. Commensalism 
The human body plays host to communities of beneficial microorganisms whose collective numbers 
exceed that of human host’s somatic and germ cells [18]. The microbial inhabitants, referred to as the 
microbiota, mediate key physiological processes in exchange for nutrients and a sheltered habitat in 
which they are able to reproduce. Strong host selection lead to their co-evolution, whereby indigenous 
microbes increased host fitness by encouraging cooperation; promoting stable functionality of the gut 
ecosystem [19]. Metagenomics has revealed the depth of this mutualistic relationship, allowing 
characterisation of the microbial flora from particular locations of the GIT, regardless of whether the 
bacteria can be cultured in the laboratory [20]. Although these microbes reside along the length of the 
gastrointestinal tract, 16s ribosomal sequencing of samples from the colon has identified that the 
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Firmicutes and the Bacteroidetes are the two dominant phylogenetic types [21]. The human gut 
microbiome consists of a huge diversity and density of commensal bacteria, which display numerical 
and strain variation according to anatomical location along the GIT. This species variation is 
dependent on local environmental conditions and substrate/nutrient availability. Generally, in healthy 
human hosts, the stomach contains a low density of commensal bacteria with species of Lactobacillus, 
Streptococcus and Helicobacter pylori predominanting. Bacterial density increases with transit down 
the GIT, where densities of 103 to 106 cfu/mL are found in the small intestine which facilitate the 
growth and survival of Streptococcus and Lactobacillus and finally, Bacteroides, Clostridium, 
Fusobacterium and Bifidobacterium reside in the large intestine/distal gut at densities of 108 to  
109 [21]. Thus, due to this strain and density variation of commensal bacteria along the GIT, the 
consequences to competition with pathogens for binding sites and nutrients, anti-microbial peptide 
production and even modulation of the host’s immune responsiveness will dramatically vary from one 
location to another in the gut. Furthermore, these beneficial stable microbiomes, found in the healthy 
host, are subject to dramatic changes in their resident populations as a consequence of pathological 
mechanisms: patients with inflammatory bowel disease (IBD) either Crohn’s disease (CD) or 
ulcerative colitis (UC) exhibit reduced microbial diversity in conjunction with disproportionate 
quantities of gram-negative bacteria when compared to healthy subjects [22].  
Exposure to microbes in early life begins with the colonisation of the newborn intestine. Infants 
born by conventional delivery are colonised at first by vaginal and faecal bacteria of the mother, 
whereas those born by caesarean section (CS) are initially exposed to bacteria originating from the 
hospital environment [23,24]. In a study of 165 births, CS infants had lower bacterial counts at one 
month of age along with significantly decreased populations of bifidobacteria compared to their 
conventionally born counterparts. Although these differences were no longer apparent at the age of  
6 months, CS infants were shown to have greater levels of IgA-, IgG-, and IgM-secreting cells, 
compared to their conventionally born counterparts, up until the study was completed at 1 year of  
age [25]. This evidence suggested that lower numbers of initial colonising bacteria, in particular 
bifidobacteria, may impede establishment of a stable gut microflora during a critical period of immune 
education and development. This would result in altered collective composition with a lasting 
influence on immune function far beyond infancy, modifying clearance efficiency of infections and 
propagation of aberrant immune responses [25].  
Diet is another important contributing factor to development of the core microbiome during early 
life. Human milk is a complex biological fluid which supplies fats, proteins, carbohydrates and 
minerals for the growing infant [26]. In addition to satisfying nutritional requirements, colostrum and 
milk have been shown to provide early immune education and passive immunity through the 
synergistic action of many bioactive molecules and cells, including immunoglobulins, lysozyme, 
lactoferrin [26] as well as being a continuous source of commensals such as L. acidophilus,  
L. gasseri [27], B. bifidium, and B. breve [28]; the compostition of which is mirrored in the infant 
during the period of breastfeeding [29]. Fernandez et al., proposed that, in addition to bacteria being 
transferred from mother to infant from the breast skin microbiota, there may be a dendritic cell- or 
macrophage-mediated trafficking of bacteria from the maternal gut epithelium to the mammary gland 
epithelium [30]. Moreover, human milk also contains a mix of oligosaccharides which do not nourish 
the infant but are instead fermented by colonic microbiota in the infant [31]. Human milk 
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oligosaccharides (HMOs) have been shown to selectively promote the growth and activity of 
bifidobacteria in vitro demonstrating prebiotic-like properties [32–34]. The exact impact of 
breastfeeding on the building of the core gut microbiome of the infant is confounded by contemporary 
practices other than caesarean delivery, including the use of antibiotics and supplementation of nursing 
with formula milk [35,36].  
The generation of germ-free (GF) mice has been an essential tool for assessing the impact of 
composition of the microbiota on the immune system as well as eluding to how particular imbalances 
can be detrimental to human health. For example, the absence of microbial stimulation in GF animals 
leads to deficits in lymphoid structures such as the spleen [37] and Peyer’s patches [38] as well as 
abnormal numbers of immune cell types [39] and expression of cytokine profiles [40]. Specific 
combinations of species have been shown to drive development of the gut associated lymphoid tissue 
(GALT) such as B. fragilis and B. subtilis, thought to enhance microfold cell transcytosis. In particular, 
protein YqxM (stress response controlled by Spo0A in sporulation of B. subtilis) is suggested to play a 
critical role, although a mutant strain (unable to sporulate but can secrete protein YqxM) was unable to 
initiate development. Either, B. subtilis must be around long enough to induce GALT development or 
additional sporulation-specific factors are also required [41].  
The effects of imbalances in gut microflora are not restricted to the gastrointestinal tract and may 
have an impact on systemic immunity, culminating in allergic disorders such as asthma and atopy [42], 
and autoimmune disease such as type 1 diabetes [43] and multiple sclerosis [44]. Specific pathogen 
free (SPF) mice have been shown to have poorly defined splenic tissue architecture and a lower 
proportion of CD4+ T-cells compared to conventional mice, with no difference in CD8+ T-cells and 
CD19+ B-cells, an effect attributed to polysaccharide A associated with B. fragalis [7]. Such 
observations further support the ‘hygiene hypothesis’ which proposes that a lack of immune 
challenges, result in the inadequate maturation of the immune system and predispose individuals to 
food allergy, asthma [45], IBD, type 1 diabetes and multiple sclerosis [46]. 
It can be concluded that the establishment and maintenance of a stable gut microbiome, through the 
appropriate exposure to commensal organisms and their prebiotic substrates as a consequence of birth, 
breast-feeding, weaning and feeding/infectious challenge, has an important impact on colonisation 
population dynamics and hence, the well-being of the host. Experimental studies have indicated the 
importance of these commensal organisms in the development of immune tissues, immune education 
and protection to immunological insults; dysregulation of these commensal populations resulting in 
immunopathology. To document the roles played by commensal and probiotic organisms in the host’s 
immune system, it is imperative to first focus on the site of initial introduction and colonisation, the 
mucosal epithelial barrier of the gut. 
3. The Mucosal Epithelial Barrier of the GIT 
The mucosal epithelia of the gut provide an enormous surface area for invading pathogens to gain 
access to the internal environment of the body. The very characteristics that make the mucosa excellent 
at physiological activities, such as absorption, also confer vulnerability to pathogenic invasion and 
infection. The integrity of this barrier can be enhanced by probiotics in a number of ways. Probiotic 
strains, such as lactobacilli and bifidobacteria, compete for adhesive access to attachment sites on 
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epithelial cells, such as those provided by mannose specific interactions [47], as well as for nutrients 
which prevents colonisation by pathogenic bacteria [48,49] (Refer to Figure 1).  
Figure 1. Probiotic and prebiotic modulation of intestinal barrier and immune responses.  
 
Prebiotics and probiotics exert a range of effects on mucosal barrier function and the responses of the 
underlying immune tissue of the GALT. Probiotic and commensal microbes (light blue rectangles), assisted 
by prebiotics (light blue strings), out-compete pathogenic organisms (red rectangles) for nutrients and 
binding sites on the epithelial cell surface (1). This barrier function is enforced by the ability of probiotics to 
influence mucin expression and mucus secretion from the goblet cells (GoC, 2) and by pathogen 
neutralisation by IgA in the mucus layer, facilitated by pIgR-mediated transcytosis of sIgA through the 
epithelial cell (3). Probiotic bacteria can induce anti-microbial peptides against pathogens either directly, as 
bacteriocins (4) or activation of epithelial cells to secrete defensins (5). Luminal gut contents are tasted by 
three mechanisms: directly via DCs extending dendrites through the tight junction and into the lumen (6), 
epithelial cell pinocytosis of microbiota (7) or by selective transfer of luminal contents via specialised 
epithelial cells, microfold (M) cells (8). Interspersed between epithelial cells, intraepithelial lymphocytes 
(IELs—predominantly CD8+) contribute to the cytotoxic, killing response of the epithelial barrier (9). The 
innate killing response can be activated in NK cells via APC production of IL-12 and the production of IL-15 
by epithelial cells (10). Immunity to extracellular parasites is elicited through B cell class switching to IgE 
production and the sensitisation of mast cells/granulocytes, which upon secondary exposure, release primary 
amines such as histamine (type I hypersensitivity) (11). Finally, the adaptive response elicited is dependent of 
the presentation responses of 6, 7 & 8. If these APCs present safe commensal/probiotic (blue) peptides, then 
tolerogenic mechanisms driven by TGFβ, IL-10 and retinoic acid are initated—resulting in suppression of T 
effector responses (Th1, Th2, Th17, Tc) and IgA production. If APCs present pathogenic peptides (red), then 
the default setting of tolerance is bypassed and as a result of the immune stimulatory cytokine environment, 
effector responses are initiated: Th1—CMI to intracellular pathogens, Th17—CMI to fungal infection and 
Th2—humoral responses to extracellular pathogens (12). Probiotics modulate this on/off switch of the 
mucosal immune system in a strain-dependant manner. Inappropriate modulation by probiotics or pathogenic 
subversion of mucosal immunity can result in immunopathology: allergy, inflammatory bowel disease  
and cancer. 
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3.1. Intestinal Epithelial Cells 
Barrier integrity is strengthened by commensals and probiotics. Enterocytes express epithelial 
growth factor receptor (EGF-R), which when activated induces enhancement of the epithelial barrier 
and tight junctions, probiotic strains have been found to promote this response [50]. Probiotic bacterial 
cell wall products such as peptidoglycan have been shown to augment apical tightening and sealing of 
tight junctions by activation of the pattern recognition receptor, TLR-2 [51]. In addition, as yet 
uncharacterised soluble factors, secreted into conditioned media by Lactobacillus rhamnosus GG, have 
been shown to up-regulate the expression of heat shock protein (hsp) 25 and hsp72 in intestinal 
epithelial cells in vitro [52,53], conferring protection against a variety of cellular stresses including 
oxidative stress-mediated apoptosis [54,55].  
3.2. Mucus 
Integral to gut barrier defence is mucus, composed of mucins. Mucins are a family of heavy 
molecular weight proteins that display extensive glycosylation and are constitutively secreted by 
goblet cells interspersed throughout the intestinal epithelium [56]. Mucin polymerisation provides the 
structural foundation of the mucus, granting protection from pathogens, enzymes, toxins, dehydration 
and abrasion [57]. Lactobacillus plantarum 299v and Lactobacillus rhamnosus GG have been shown 
to up-regulate production of MUC2 and MUC3 intestinal mucins which subvert the adherence of the 
enteropathogenic bacterium Escherichia coli O157:H7 to intestinal epithelial cells, consequently 
preventing pathogenic bacterial translocation [58]. It is thought that this probiotic-mediated 
modulation of mucin expression is a strategy for intestinal colonisation of beneficial microbes to the 
host [59]. Furthermore, mucins may exert prebiotic-type effects as carbohydrate content can account 
for 90% of their weight [60]. Molecular cloning of glycoside hydrolases from Bifidobacterium bifidum 
have been shown to specifically catalyse oligosaccharides that exist within mucins which can be used 
as an energy source [61,62].  
3.3. IgA 
Protease-resistant IgA is integral to barrier function, playing an important role in trapping 
pathogens/pathogenic material (neutralisation) in the mucus layer through its ability to bind  
mucins [63]. Probiotic strains such as Lactobacillus GG, Bifidobacterium lactis Bb-12 [64] and 
Saccharomyces boulardii [65] have been demonstrated to enhance IgA production and secretion 
through alteration of the cytokine milieu in the gut mucosa. Probiotic bacteria have been shown to 
induce epithelial cell expression of TGFβ and IL-10 as well as IL-6 which potentiate IgA production 
through B-cell maturation and class-switching in favour of IgA [66,67]. Finally, probiotics can 
induce/augment the expression of polymeric Ig receptors on the basolateral surface of intestinal 
epithelial cells enhancing transcytosis of IgA through the epithelial cell and into the glycocalyx/gut 
lumen [68].  
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3.4. Antimicrobial Peptides 
Also important to barrier defence against pathogenic microbes is the ability of epithelial cells, 
probiotics and commensals to produce antimicrobial peptides (AMPs). Bacteriocins are antimicrobial 
peptides produced by the majority of bacterial organisms that are thought to contribute to probiotic 
functionality by assisting with colonisation [69,70], direct elimination of pathogens [71] and acting as 
signalling molecules directing other bacteria or the host immune system [72]. Many studies have 
shown that production of bacteriocins by microbiota can lead to sustained presence of beneficial 
bacterial strains in the GIT. A study using a Lactobacillus strain mix demonstrated an improved 
clinical outcome of pigs infected with Salmonella, attributable to the production of bacteriocins by 
Lactobacillus salivarius [73]. This is supported by a study using Pediococcus acidilactici probiotic 
which reduced the viability of Listeria monocytogenes [74]; an effect unobservable in vivo. The  
anti-microbial peptide lacticin also failed to protect against infection from Listeria monocytogenes [33], 
highlighting a possible variance in bacteriocin efficiency in vivo. In the case of C. difficile infection, a 
targeted approach using Bacillus thuringiensis which produces the narrow-spectrum bacteriocin, 
thuricin CD, is highly effective at killing C. difficile whilst having no significant impact on the 
microbiota composition [75]. In contrast however, broadspectrum bacteriocins such as lacticin 3147 
produced by Lactococcus lactis subsp. lactis DPC3147 has been shown to negatively impact on 
members of the Firmicutes and Bacteroidetes [76].  
Defensins are a family of highly conserved small cysteine-rich AMPs particularly abundant at 
mucosal sites where they contribute to the host defence by disrupting the cytoplasmic membrane of 
susceptible microorganisms [77,78]. Paneth cells, residing within the epithelium at the bottom of 
intestinal crypts, secrete defensin-rich granules upon exposure to bacterial products such as LPS, LTA 
and muramyl dipeptide [79]. A study using healthy human subjects demonstrated that probitotic 
Escherichia coli Nissle 1917 was able to induce human beta-defensin (hBD)-2 [80], mediated by 
flagellin-dependent NF-kappaB- and AP-1 pathways [81]. In addition, probiotic Lactobacilli strains 
are not only able to up-regulate enterocyte hBD-2 production in vitro [82]; some species, such as 
Lactobacillus lactis, have been demonstrated to be resistant to the anti-microbial effects of this 
defensin [83]. Furthermore, as well as their role as AMPs, hBD1 and hBD2 have been reported to play 
a more direct role in modulating host immunity, acting as chemoattractants for T cells and immature 
dendritic cells through binding CCR6 [84]. 
3.5. Intraepithelial Lymphocytes 
Invasive enteropathogenic bacteria such as E. coli, Salmonella typhimurium or Clostridium difficile 
can cause intracellular infection of host cells. Located within the epithelium are intraepithelial 
lymphocytes (IELs) these are a diverse group of cells, predominantly consisting of CD8+ T cells,  
sub-divided by their differential TCR expression; either the γδ- or αβ-TCR. Intraepithelial γδ cells 
have been shown to respond to affected enterocytes within hours of infection by secreting the 
antibacterial lectin, RegIIIγ, or directly lysing cells using a natural killer-like effector killing 
mechanism. These γδ IELs express the receptor NKG2D which responds to host cells displaying signs 
of infection and cellular stress [85,86]. Interestingly, a recent study using the TNBS-experimentally 
Nutrients 2013, 5 1876 
 
 
induced colitis model demonstrated that treatment with a mix of L. acidophilus and B. longum 
probiotics suppressed inflammatory destruction of the gut which was associated with the influx of γδ+ 
IELs, increased CD4+ Treg populations and IL-10 within the area and a corresponding down-regulation 
in CD4+ T effector cells and pro-inflammatory cytokines [87]. 
The Aryl hydrocarbon receptor (AhR) is heavily expressed by IELs, ligation of which is necessary 
in maintaining IELs within the gut mucosa, preventing their migration away from this site to elsewhere 
in the system. The ligand for the receptor is found in cruciferous vegetables, and it has been shown that 
a reduction in AhR expression leads to increased bacterial load in the gut and increased tendency 
towards colitis [88]. Ligation of the AhR receptor is a mechanism for Treg induction, and has been 
used experimentally to supress Th2 mediated allergy to peanuts via induction of CD4+CD25+Foxp3+ 
Tregs [89]. Within the mucosa the AhR signalling pathway was triggered experimentally by  
L. plantarum a common probiotic found in food, and observed to promote inhibitors of the NF-κB 
pathway which suggested that this probiotic induces tolerance to food antigens [90]. 
It is thus becoming apparent that the commensal/probiotic, mucus/glycocalyx and epithelial cell 
barriers are not just physical and chemical barriers to pathogenic infection, but represent a clear 
communication system resulting in direct modulation of host-driven immune responses. 
4. Immunomodulatory Role of Probiotic Bacteria 
The gut mucosal epithelium not only acts as a barrier to unwanted pathogenic organisms but 
represents a mechanism of safely and selectively tasting luminal contents of the gut, passing this 
information underneath the barrier to the immune cells/tissue of the GALT in the lamina propria and 
beyond in the mesenteric lymph nodes. This selective tasting of the contents of the GIT is the way in 
which the host tolerates that which is beneficial non-self (through the mechanism of immune 
tolerance/hyporesponsiveness) and mounts protective immune responses to that which is pathogenic 
non-self (through humoral and cell-mediated immune mechanisms). The process by which this 
antigenic information is passed to the underlying cells is crucial to this immune fate: 
tolerance/suppression versus activation. There are generally three mechanisms in which antigenic 
material is processed and presented to the underlying immune cells and that these mechanisms are 
controlled by three different types of antigen-presenting cells (APCs) (refer to Figure 1). 
4.1. Tasting of Luminal Contents 
These three main cell types, which communicate information about the microflora and the digesta 
to underlying immune cells are epithelial cells, specialised epithelial cells called microfold (M) cells 
and dendritic cells (DCs). Epithelial cells or enterocytes, at the apical surface, are linked by tight 
junctions preventing the penetration of microbial pathogens; these cells however, can facilitate 
vesicular bacterial/antigenic transfer across the barrier by receptor-mediated pinocytosis. Once inside 
the cell, antigenic material can be processed and presented in the context of a major histocompatibility 
complex molecule (MHC) expressed with co-stimulatory molecules on the basolateral membrane, 
thereby activating lymphocytes located beneath in the lamina propria [91,92]. Although enterocytes/ 
epithelial cells are antigen presenting cells (APCs); in the presence of inflammation, it has been shown 
that under normal circumstances they fail to express the co-stimulatory molecules (CD80 or CD86) 
Nutrients 2013, 5 1877 
 
 
required for activation of lymphocytes. Thus, they function to induce anergy in CD4+ T cells and 
therefore induce a tolerant environment in the presence of commensals [93].  
Gut mucosal DCs represent the second mechanism of sampling luminal contents and priming 
immune activation or tolerisation. In a safe environment of commensal organisms and beneficial 
dietary components, immune activation is suppressed by TGF-β and TSLP, secreted by epithelial  
cells in response to commensal bacteria, hence promoting a default non-inflammatory humoral 
environment [94,95]. Ligation of TLRs on the apical surface of enterocytes has been linked to DC 
activation which, via a fractalkine receptor CX3CR1-dependant mechanism, project arm-like 
extensions (dendrites) between the tight junctions of the epithelial barrier allowing them to 
independently sample the luminal contents [96,97]. Upon sampling, DCs become influential APCs, 
having phagocytosed antigen they can migrate to mesenteric lymph nodes where they stimulate 
lymphocyte proliferation, or they can activate localised lymphocytic cells. This mechanism is 
important for the sampling of luminal contents without reducing transepithelial resistance/barrier 
integrity [98]. 
The third cell type which enables the cross talk between the microbiota and the host’s immune 
system is the microfold (M) cell, located within the epithelial monolayer above areas of follicular 
lymphoid tissue referred to as Peyer’s Patches. Here M cells form a gateway, transcytosing microbes 
and allowing controlled access to a range of immune cell types, inducing expansion and activation of 
follicular lymphocytes [99]. Unlike enterocytes they do not secrete anti-microbial components or 
present antigen, but instead shuttle macromolecules and microorganisms to other effector cells such as 
DCs and macrophages present in the M cell pocket. However, certain pathogens have evolved to 
recognise M cells as the entry point into the host’s tissue, thus evading detection by other epithelial 
surveillance mechanisms [100].  
4.2. Recognition of Pathogenic and Commensal Bacteria 
Recognition of luminal bacteria as either commensal or pathogenic is of great importance to the 
mucosal immune system in eliciting positive immune activatory- or negative, tolerising-responses. 
Innate pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs) respond to pathogen 
associated molecular patterns (PAMPs) and are expressed by enterocytes and mucosal APCs (DCs and 
macrophages). The binding of PAMPs to these innate receptors triggers intracellular signalling 
cascades, resulting in the release of specific cytokines, exerting anti-viral, pro- or anti-inflammatory 
effects on neighbouring cells. The expression of TLRs is down-regulated on the apical membrane of 
the epithelial barrier in comparison to the basolateral side; TLR2 and TLR4 are expressed at low levels 
on the apical surface and drive tolerance to LPS and peptidoglycan, expressed in the cell walls of 
commensal bacteria [101]. Equally, basolateral activation of TLR5 by flagellin, a common component 
of pathogenic bacteria, leads to a heightened pro-inflammatory response, resulting from the 
translocation of pathogenic flagellin across the epithelium. No such translocation, hence  
pro-inflammatory response, was observed for commensal E. coli flagellin [102]. Indeed, healthy, 
homeostatic colonic epithelial cells were observed to be unresponsive to bacterial flagellin whereas 
flagellin that had gained entry to the basolateral surface elicited a TLR5-dependant inflammatory 
response [103]. This provides a defensive strategy against virulent pathogens, which gain entry by 
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circumnavigating the antigen processing and presentation pathways. Indeed, exposure to virulent 
pathogenic bacteria induces epithelial cell secretion of IL-8, a chemokine initiating the recruitment and 
infiltration of neutrophils and commencement of inflammation [104]. The ingestion of the probiotic 
culture VSL#3 however, has been linked to a dampening down of this response, reducing IL-8 
secretion even in the presence of pathogenic Salmonella dublin [105].  
A large proportion of the indigenous bacteria are Gram-negative which accounts for a high LPS 
load. Intestinal alkaline phosphatase can be expressed by epithelial cells under the control of LPS, 
originating from normal microbiota [106]. This enzyme is thought to cleave glutamine and phosphate 
from LPS moieties [107], leaving a dephosphorylated LPS that is unable to activate TLR4 signalling; 
effectively suppressing proinflammatory responses such as neutrophil activation [108]. Importantly, 
the localisation of intestinal alkaline phosphatase is largely confined to the apical surface [109]; 
allowing modification of luminal LPS whilst allowing an immune response to be initiated upon 
successful bacterial invasion and breaching of the epithelial barrier. This is indicative of a fine balance 
of bacterial PAMP recognition that descriminates between activation and tolerisation. Indeed, in 
addition to positive activatory immune mechanisms, recognition of bacterial PAMPs can exhibit 
inhibitory mechanisms. These mechanisms include a range of strategies to suppress TLR-mediated 
activatory signals including; (i) reduction in TLR expression, (ii) expression of shed/secreted receptors 
(sTLR2, sTLR4, sCD14, sST2), (iii) expression of decoy receptors (SIGIRR, ST2L, RP105) and  
(iv) expression of endogenous inhibitors of TLR signalling pathways (Myd88s, Tollip, A20, IRAK-M, 
SARM, TRAIL-R, ATF-3, TRIAD3A and possibly NOD2). These strategies have been described to be 
employed by a range of cells including IECs and monocyte/macrophage lineage cells that are vital to 
gut mucosal immune functionality (reviewed in [110]). 
4.3. Lumenal Contents Determine Immune Fate: Tolerance or Activation? 
These processing and presentation pathways mediated by epithelial cells, DCs and M cells are 
pivotal to immune fate decisions upon tasting the gut luminal contents. In the context of safe non-self 
or harmful non-self (utilising TLRs), these cells pass on the antigenic information resulting in immune 
regulation/tolerance or immune activation. In safe, homeostatic environments, antigenic sampling 
results in mucosal tolerance that is dominated by regulatory T cells (Tregs). CD4+ Tregs are key to the 
negative regulatory component of immune responsiveness, acting to suppress unnecessary inflammation 
and the differentiation of effector cells, such as T-helper (Th) cells and cytotoxic T-cells (Tc).  
In comparison to other T-cell subsets, Tregs express increased levels of CD25 (IL-2Rα) and the 
endogenous co-stimulatory inhibitor, CTLA-4, with the majority of CD4+ CD25+ Tregs expressing the 
Treg marker, Foxp3. The presence of Foxp3 is essential for Treg differentiation, leading to the 
production and secretion of anti-inflammatory/regulatory cytokines, such as IL-10 and TGF-β, which 
mediate Treg suppressive effects [111,112]. In pathologies whereby negative signalling is defective, 
the therapeutic reinstatement of a tolerogenic setting, through up-regulation of regulatory mediators or 
the down-regulation of pro-inflammatory mediators, can result in the resolution of chronically 
inflamed tissue. One characteristic feature of some probiotics is the ability to suppress  
pro-inflammatory responses through the up-regulation of tolerogenic mechanisms. 
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A number of mouse model experiments conducted to observe the effects of probiotic administration 
have identified a ubiquitous characteristic in both Lactobacillus and Bifidobacterium strains.  
Lavasani et al., using mice with developing encephalomyelitis, identified that L. paracasei and  
L. plantarum induced CD4+ CD25+ Foxp3+ T-regs in mesenteric lymph nodes leading to increased 
TGF-β levels and reduced inflammation in the CNS [113]. Other studies have confirmed this 
immunomodulatory effect, with a range of Lactobacillus strains shown to increase TGF-β and IL-10 
levels [114–116]. Many of the aforementioned studies also found probiotic mediated inhibition of  
pro-inflammatory cytokines including IFNγ, IL-6 and TNFα, further supporting the role for probiotics 
in suppression of pro-inflammatory immunity. There is, however, a study which conflicts with these 
findings, demonstrating the ability of L. acidophilus and L. salivarius to decrease IL-10 and TGF-β 
levels in the rectum of BALB/c mice. The study further observed no differences in Treg modulation of 
bystander T-cell function, between control and probiotic-fed mice [117]. The findings of this study, 
despite being uncharacteristic, may demonstrate anatomical and strain variance in probiotic 
immunomodulatory function. 
To address the mechanisms behind probiotic induced Treg activation, studies have explored the role 
of probiotics in modulating DC function. L. reuteri and L. casei have been found to prime DCs to 
produce increased levels of IL-10 and inhibit the proliferation of bystander effector T-cells; an effect 
found to involve probiotic engagement of the C-type lectin, DC-SIGN [115]. B. breve has also been 
identified as a mediator of IL-10 production, however unlike the Lactobacillus strains, was found to 
act through MyD88-dependent TLR-2 signalling in CD103+ DCs [116]. Engagement of TLR2 has 
been shown to result in the rapid release of IL-10, which subsequently inhibits opposing cytokines 
such as the Th1-polarising cytokine, IL-12 [118] and CD103+ DCs are known to induce Foxp3+ T-cells 
in a TGF-β and retinoic acid (RA)-dependent manner [119]. Collectively, this suggests mechanisms by 
which probiotics interact with DC subtypes to induce a tolerogenic setting predominated by  
anti-inflammatory cytokines, IL-10 and TGF-β. These studies also highlight Lactobacillus as 
activators of conventional DCs and Bifidobacterium as activators of CD103+ DCs, implying strain 
variance in DC-subset targeting and functionality.  
4.4. Cytokines Are Pivotal to This Immune Cell Fate 
It is well established that immune fate decisions (activation or tolerance) are made by immune cells, 
which are activated by, and elicit an effector response by specific functionality and profiles of the 
immune cell signals, cytokines. Environmental cytokines can elicit pro-inflammatory responses 
(TNFα, IL-1β, IL-6, IL-8, IL-15) and anti-inflammatory/suppressive responses (IL-10, TGFβ), through 
the direction of a wide array of effector cells which include granulocytes, macrophages, DCs, T & B 
cells. In addition, cytokines drive Th1 differentiation (IL-12) hence CMI via IFNγ, Th2 differentiation 
(IL-4) and humoral responses via IL4, IL-5, IL-13, IL-10; Th17 differentiation (TGFβ, IL-1β, IL-6 & 
IL-23) and anti-pathogen responses via IL-17A and IL-22, Treg differentiation (IL-10, TGFβ, IL-35) 
and suppression via the production of IL-10, TGFβ and IL-35 (refer to Figure 1). There is a wealth of 
research literature which documents the ability of probiotics to modulate cytokine production; either 
via immune activation/augmentation, immune deviation or suppression. Modulation of such cytokine 
expression will have an appreciable impact on immune functionality and represents a clear avenue of 
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manipulation for probiotic use in the treatment and prophylaxis of immunopathology. Many 
Lactobacillus strains have been described to induce IFNγ and IL-12, which are Th1-cytokines 
associated with CMI and NK activity whereas other Lactobacillus strains both augment and suppress 
the Th2-associated cytokines, IL-4 and IL-5, which drive humoral immune responses. More recently, 
Evrard et al. [120], has described L. rhamnosus to induce IL-23, an IL-12 family member associated 
with Th17 differentiation and pro-inflammatory responses. Additionally, a wide range of both 
bifidobacteria and Lactobacillus induce expression of the anti-inflammatory/regulatory cytokines, 
TGFβ and IL-10, associated with Treg suppressive function/tolerance (for a full citation of probiotic 
modulation of T cell differentiation/functionality, refer to Table 1). 
Table 1. Probiotic strains differentially modulate T cell differentiation and effector cytokines. 
Cytokines (Immune Response) Cell system Response Probiotic strain References 
IFN-γ & IL-12 (Th1-associated, 
CMI and NK cell activity) 
PBMCs Increase 
L. rhamnosus [121] 
L. plantarum 
L. lactis 
L. casei 
L. rhamnosus GG 
[122] 
L. lactis W58 [123] 
L. casei Shirota [124] 
L. casei Shirota [125] 
L. paracasei 
L. salivarius 
[126] 
B. longum W11 [127] 
L. rhamnosus 
L. gasseri 
B. bifidum 
E. coli (TG1) 
[128] 
L. casei Shirota [129] 
L. plantarum strains [130] 
PBMC-Mo Increase 
S. aureus  
L. johnsonii 
[114] 
PBMC-DCs Increase 
L. salivarius  
L. rhamnosus Lcr35 
[131] 
[120] 
PBMC-NK cells Increase 
L. acidophilus 
L. reuteri 
[132] 
Myeloid DCs Increase 
L. gasseri 
L. johnsonii 
L. reuteri 
[133] 
PBMC-NK cells Decrease B. bifidum [132] 
IL-23 & IL-17 (Th17-associated, 
pro-inflammatory) 
Mo-DCs Increase L. rhamnosus Lcr35 [120] 
PBMCs Decrease 
B. breve  
LGG 
[134] 
Caco-2 cell line Decrease L. plantarum [135] 
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Table 1. Cont. 
IL-4 & IL-5 (Th2-associated, 
humoral)  
PBMCs Decrease 
L. plantarum 
L. lactis 
L. casei 
L. rhamnosus GG 
[122] 
Bifidobacteria [123] 
L. rhamnosus 
L. gasseri 
B. bifidum 
[128] 
TGF-β (Treg-associated,  
anti-inflammatory) 
PBMCs Increase B. longum [136] 
Epithelial cells Increase 
B. lactis 
L. johnsonii 
[137] 
Overview of studies documenting the probiotic strain-specific effects on Th1 cytokines (IFNγ and IL-12) 
associated with cell-mediated immunity, Th17 cytokines (IL-23 and IL-17) associated with pro-inflammatory 
anti-pathogen responses, Th2 cytokines (IL-4 and IL-5)—humoral immunity and Treg (TGFβ) associated 
with immune tolerisation/suppression. All studies are human studies utilising a range of cell sources: peripheral 
blood mononuclear cells (PBMCs), NK cells, DCs, monocytes (Mo) and Caco-2 gut epithelial cells. 
In addition to differentiating CD4+ T helper cells to distinct lineages responsible for cell mediated 
immunity and humoral immune responses, probiotics also have an important role in the modulation of 
innate inflammatory responses important for early, non-specific anti-pathogen responses and a 
potential role in the regulation of chronic inflammatory responses. A range of both Lactobacillus and 
Bifidobacterium species augment the secretion of TNFα, IL-1β and IL-6 by PBMCs, DCs, monocytes, 
macrophages and epithelial cells. In contrast there is both a differential and overlapping probiotic 
strain induction of the anti-inflammatory cytokine, IL-10. Of particular interest is the suppressive 
effect of L. casei Shirota on PBMC production of IL-10 [129], an effect which may be explained by 
the documented effect of LcS on the induction of the Th1-polarising cytokine, IL-12. (For a full 
citation of probiotic modulation of inflammatory cytokines, refer to Table 2). 
Finally, one of the greatest producers of cytokine is the tissue macrophage. These cells are present 
in large numbers in the lamina propria of the GIT and, as such, play an important role in driving 
immune responsiveness in the gut. These mucosal macrophages exhibit a degree of functional 
plasticity which is determined by the local tissue environment. As such, macrophages can exist as  
M1-like pro-inflammatory and M2-like anti-inflammatory/regulatory subsets (reviewed in [138]). 
Recently, probiotic strains have been described to differentially regulate macrophage cytokine 
production in a strain- and subset-specific manner [139,140]. The inflammatory response being 
dictated by both the probiotic strain and which macrophage subset is being activated, hence macrophage 
populations can display differing inflammatory outcomes as a consequence of which subset is 
predominant in the tissue environment being challenged. Of relevance to prebiotic research, the SCFA, 
butyrate, produced as a consequence of anaerobic fermentation of prebiotic non-digestible carbohydrates, 
has also been demonstrated to play a role in macrophage cytokine production; again, the inflammatory 
cytokine outcome being determined by macrophage subset [141]. Thus, cytokines determine immune 
responsiveness to commensals, pathogens or in the case of dysregulation, immunopathology. 
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Table 2. Probiotic strains differentially modulate pro- and anti-inflammatory cytokines. 
Cytokines (Immune Response) Cell system Response Probiotic strain References 
TNF-α and IL-1β  
(Pro-inflammatory) 
PBMCs Increase 
L. rhamnosus 
L. bulgaricus 
S. pyogenes  
[121] 
Bifidobacteria  [142] 
L. casei Shirota [124] [129] 
L. salivarius 
L. fermentum [143] 
L. plantarum strains [130] 
PBMC-DCs Increase L. rhamnosus Lcr35 [120] 
Myeloid DCs Increase L. reuteri [133] 
Epithelial cells Increase L. sakei [137] 
Macrophage 
subset cell line 
Increase and decrease 
(subset-specific) L. casei Shirota 
[139] 
[140] 
THP-1 cell line Decrease L. reuteri [144] 
IL-6 (Pro-inflammatory) 
PBMCs Increase 
L.rhamnosus 
L. bulgaricus 
S. pyogenes 
[121] 
Epithelial cells Increase 
B. lactis Bb12 
L. casei CRL431 
L. helveticus R389 
[145] 
[146] 
PBMCs Decrease L. casei Shirota [129] 
IL-10 (Anti-inflammatory) 
PBMCs Increase 
Bifidobacteria DNA [147] [123] 
Bifidobacteria [142] 
B. longum W11 [127] 
L. fermentum [143] 
L. acidophilus 
L. plantarum strains [130] 
L. acidophilus 
L. reuteri [132] 
PBMC-NK cells Increase 
B. bifidum  
VSL#3 
L. reuteri 
[147] 
[115] 
Blood-DCs Increase L. plantarum 
Mo-DCs Increase 
L. casei 
L. rhamnosus 
Bifidobacteria 
[148] 
[149] 
Mo-DCs Increase 
B. infantis [150] Mo-DCs, 
mDCs, pDCs Increase 
PBMCs Decrease L. casei Shirota [129] 
Overview of studies documenting the probiotic strain-specific effects on the pro-inflammatory cytokines 
(TNFα, IL-1β and IL-6) and the anti-inflammatory cytokine, IL-10. All studies are human studies utilising a 
range of cell sources: peripheral blood mononuclear cells (PBMCs), NK cells, DCs, THP-1 pro-monocytic 
cell line, macrophage subsets and intestinal epithelial cells. 
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5. Immunopathology and Probiotic/Prebiotic Immunomodulation  
5.1. Th1/Th17-Dominant Pathology, Crohn’s Disease 
The balance between humoral and cell mediated immunity is important for a healthy immune 
response, there are a range of pathologies in which a bias in the cytokine and cell differentiation profile 
are observed. In these cases a dysbiosis of the gut microbiota is often seen, thus the use of probiotics to 
counteract this has been the focus of many research papers. The understanding of individual variations 
in gut flora is widening with the recent advances in DNA sequencing and proteomics technologies, 
allowing in-depth analysis of the strains present in the human GIT, both in health and disease. There is 
however often a genetic predisposition which leads to an altered response to bacteria, here we review 
the mechanisms underlying pathology and the potential for using probiotics and symbiotics as a 
therapeutic tool. Crohn’s is an inflammatory bowel disease, which can affect any part of the GIT; it is 
characterised by transmural granulomatous inflammation with high expression of IL-12/IL-23 and an 
associated predominance of CD4+ Th1/Th17 cells, leading to the secretion of IFN-γ, TNFα and  
IL-17 [151] (refer to Figure 1). 
Th17 cells are a CD4+ expressing Th1-like subset, activated by IL-23 and IL-6 to produce IL-17, 
IL-22 and IL-26 (reviewed in [152]). Pro-inflammatory, Th17s and IL-17 are of growing importance to 
immunological research due to their emerging role in inflammatory pathologies including rheumatoid 
arthritis, Crohn’s disease, cancer and dermatitis [153]. As probiotics are able to modulate both Th1 and 
Th2 mediated responses, attention drew to potential use in modulating Th17 cells. Several studies have 
focussed on probiotic modulation of IL-17 and IL-23. Paolillo et al. [135] found L. plantarum 
treatment with LPS-activated Caco-2 epithelial cells reduced IL-23, suggested to be a TLR-2 
dependent mechanism; a cytokine finding supported by Ghadimi et al. [134] who observed a reduction 
in IL-17 and IL-23 in PBMCs co-cultured with human intestinal cells and treated with B. breve and  
L. rhamnosus GG. In contrast, a study using human monocyte-derived DCs found IL-23 to be induced 
upon treatment with L. rhamnosus [120]. Evrard et al. further found L. rhamnosus to increase CD86 
and DC-SIGN expression on human DCs suggesting the effects of Lactobacillus on Th17 activation to 
be mediated through modulation of DC function [120]. These co-culture system studies are more 
applicable to in vivo settings; in which case particular probiotic strains may have a role in inducing 
Th17-mediated immunity through modulation of DCs affecting down-stream pro-inflammatory 
cytokine expression. 
Crohn’s sufferers display a shift in commensal bacterial populations towards higher numbers of 
Gram-negative Proteobacteria and lower numbers of Gram positive Firmicutes, there is also a 
dysbiosis in the genera Bacteroides with a higher expression of B. ovatus and B. vugatus and lower 
expression of B. uniformis [154,155]. It is believed that a dysregulated pro-inflammatory response is 
elicited in those with genetic mutations in pathogen-sensing receptors such as the CARD15 gene 
encoding NOD2, a cytosolic protein expressed by epithelial cells, paneth cells, dendritic cells and 
macrophages and is involved in the sensing of bacterial cell wall peptidoglycan [156,157]. The NOD2 
pathway is linked to activation and regulation, of NF-κB and expression of proinflammatory cytokines 
TNFα IL-1β, IL-12 and anti-bacterial peptides, as well as transcription of apoptotic genes. There is 
some disagreement however, as to the impact mutations may have in Crohn’s disease, as there are  
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30 function mutations in NOD2 thus the impact on immunity is highly variable [156,158]. It would 
seem that an increase in IL-1β may be partially responsible [156]. Although it has been suggested that 
NOD2 plays a role in the production of anti-inflammatory IL-10 and TGF-β and thus loss of function 
mutations may result in a loss of tolerance to commensals [159]. It is believed that these mutations, 
acting in combination with the strains of bacteria present in the GIT, result in an excessive 
proinflammatory response [158]. As previously noted there is a marked reduction in the numbers of 
Firmicutes found in the GIT of patients with Crohn’s, specifically the beneficial commensal 
Faecalibacterium prausnitzii [160]. A recent study used this strain as a probiotic both in vivo and  
in vitro, and found that oral administration of the live bacterium lead to reduced evidence of 
experimental colitis in mice [160]. A marked increase in IL-10 secretion and significant reduction in 
IFNγ and IL-12 production was seen in PBMC exposed to this probiotic, thus it is suggested as a 
potential therapeutic strategy in Crohn’s disease [160,161]. Interestingly, there could be a correlation 
between this bacterium and transepithelial resistance as F. prausnitzii is a butyrate producing bacteria, 
and butyrate is a metabolic source for the catabolism of ATP vital for host epithelial cell  
metabolism [161,162]. A diet rich in prebiotic short chain fatty acids provides a supporting role for the 
butyrate-producing commensals [163,164]. The dietary prebiotic inulin which is contained in bananas, 
tomatoes, onions, garlic and Jerusalem artichokes has been shown to be a prime source of nutrients for 
F. prausnitzii and therefore future developments in the treatment of Crohn’s could involve symbiotic 
preparations of inulin and F. prausnitzii [165,166]. (Refer to Table 3). 
Table 3. Probiotic strains, prebiotics and synbiotics differentially modulate immunopathology. 
Pathology Response Probiotic/Prebiotic References 
Crohn’s 
↓ IFN-γ, IL-12  F. prausnitzii  [160] 
↑ IL-10 Fructo-oligasaccharides [167] 
Ulcerative 
colitis  
↓ IL-1β, TNF-α, IFN-γ, IL-12  L. plantarum 299v [168] 
LGG [169] 
↑ IL-10 LGG [169] 
↓ β-defensins, TNF-α, IL-1, CRP B. longum/Synergy 1 [170] 
↓ CRP B. longum/psyllium [171] 
↓ adherence of B. vulgatas LGG [172] 
↓ expression of tight junction proteins VSL#3 [172] 
↓ tissue inflammation VSL#3 [173] 
↑ no. γδ IEL  
↓ no. γδ T-cells in lamina propria  
↑ no. T-regs 
L. acidophilus + 
B. longum  
[87] 
Reshape microbiota composition VSL#3 [174] 
Colorectal 
Cancer 
↓ aberrant crypt formation 
↓ cecal pH 
Bifidobacteria + 
Lactobacilli + 
Inulin + 
Oligofructose 
[175] 
↑ SCFA production 
↓ IL-2 and iNOS 
Bifidobacteria + 
Lactobacilli + 
Inulin + 
Oligofructose 
[176] 
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Table 3. Cont. 
Colorectal 
Cancer 
↓ H2O2 
↓ tissue inflammation 
↑ catalase activity 
L. lactis [177] 
↓ IL-2 and iNOS B. lactis [176] 
L. rhamnosus  [178] 
↑ angiostatin 
↑ no. CD4+ T-cells 
↑ IL-17 and TNF-α 
VSL#3 [179] 
↓ CXCR4 mRNA expression  
↓ MHC-class 1  
↓ tumour growth  
↑ CT-26 cancer cell apoptosis 
L. acidophilus [180] 
Allergy 
↓ IL-4 and IL-5 L. plantarum [122] 
↑ IL-12 and IFN-γ L. lactis [181] 
L. plantarum [128] 
↓ IL-5, IL-4 and IL-13 B. breve + oligosaccharide [182] 
↑ no. CD4+CD25+Foxp3+ T-regs AhR ligand (TCDD) [89] 
↓ IL-12 
↔ no. T-regs B. breve + oligosaccharide [183] 
↑ no. bifidobacteria colonies 
↓ no. Clostridium colonies 
↓ faecal pH 
↔ IgE 
↔ levels of acetic acid 
B. breve + oligosaccharide [184] 
Coeliac 
↑ no. CD4+ T-cells 
↑ IFN-γ L. casei [185] 
↑ transepithelial resistance B. lactis [186] 
↑ IL-12 and IFN-γ Shigella CBD8 [187] 
↑ TNF-α 
B. bifidum 
L. paracasei 
L. fermentum 
[187] 
[188] 
Overview of studies documenting the role of probiotic strains, prebiotics and synbiotic formulations and their 
effects on Crohn’s disease, Ulcerative colitis, colorectal cancer, allergy and coeliac’s disease. All studies are 
human studies detailing potential modulation of a variety of disease markers and immunological functional 
readouts. Arrows indicate decreases (↓), increases (↑) or no change (↔). 
In addition to Th1 cells, Th17 cells are also prevalent in this pathology due to an imbalance in the 
suppressive Treg population and proinflammatory Th17 cells, with a bias towards the latter.  
This effectively tips the balance away from tolerogenic Treg activity towards chronic inflammation 
due to increases in Th1/Th17 and IL-12/23 expression [189,190]. A recent clinical trial used prebiotic 
fructo-oligosaccharides in Crohn’s disease patients and found an increase in the numbers of  
immune-regulatory dendritic cells and heightened the concentration of IL-10 secreted by intestinal 
dendritic cells, yet these factors did not reduce the clinical presentation of the disease [167]. A further 
trial, using a symbiotic combination of Bifidobacterium longum, B. breve and Lactobacillus casei with 
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prebiotic psyllium, which comes from barley however, resulted in a significant decrease in clinical 
scoring of the pathology [191]. Just what the beneficial effects of these symbiotic formulations are to 
the immunological mechanisms will be a focus of future research endeavours. It can be suggested 
however, that any beneficial effect would result from immunomodulation of DC/APC function, cytokine 
production and T-helper differentiation/effector function towards a regulatory/suppressive phenotype. 
5.2. Immunopathology: Th2-Dominant Pathology, Ulcerative Colitis 
Ulcerative Colitis (UC) is an inflammatory bowel disease characterised by diarrheoa, abdominal 
pain and rectal bleeding. Pro-inflammatory mediators, such as TNF-α, are up-regulated in UC, 
suppression of which has been proven to effectively reduce mucosal damage, colonic infiltration of 
macrophages and neutrophils and UC-associated tumour growth [192] (refer to Figure 1). As an 
idiopathic disease, the precise aetiology is unknown however the role of commensal bacteria and 
dysbiosis has emerged as potential causal factors [193]. Current treatments for IBD include  
anti-inflammatory drugs, dietary changes and surgery, but with the suggestion of commensal bacteria 
playing a role in pathogenesis, the therapeutic use of probiotics is being explored.  
The rationale behind probiotic therapy lies in the ability to modulate immune response. As UC is a 
predominant Th2-driven pathology, skewing of the immune response to a more tolerogenic tissue 
environment may alleviate the damaging effects of a dysregulated inflammatory response. Current 
therapies do aim to dampen-down these inflammatory responses, however patient responsiveness is 
variable and surgical procedures invasive; therefore probiotics pose an alternative, non-invasive 
therapeutic option. Of the studies conducted in UC mouse models, a number of Lactobacillus strains 
have been identified to modulate pro-inflammatory responses. Both L. plantarum 299v in IL-10 
knockout mice [168] and L. rhamnosus GG in transgenic mice [169] have been shown to decrease 
levels of pro-inflammatory cytokines including IL-1β, TNF-α, IFN-γ and IL-12. Furthermore, levels of 
the anti-inflammatory cytokine IL-10, was augmented upon administration of L. rhamnosus GG [169]. 
In addition to direct immunomodulation, Lactobacillus alters epithelial barrier function: L. rhamnosus 
GG was found to decrease adherence of pathogenic B. vulgatas whereas the probiotic mix VSL#3 
decreased expression of tight junction proteins, occludin, zonulin and claudin and prevented epithelial 
cell apoptosis in BALB/c mice [172]. VSL#3 has also been shown to reshape bacterial composition 
through enhancing species richness and diversity index [174]. In clinical trials, these findings have 
been related to gross pathological changes, with evidence of decreased tissue inflammation and 
enhanced disease remission and clinical responsiveness [173,194]. These studies clearly demonstrate 
the ability of probiotics to modulate the immune response in UC, skewing a predominant  
pro-inflammatory setting towards a more tolerogenic environment, characterised by down-regulation 
of pro-inflammatory cytokines such as TNFα, IL-1β and IFNγ and an up-regulation of  
anti-inflammatory cytokine IL-10. These effects appear to confer a health benefit, with evidence of 
enhanced epithelial barrier function, decreased tissue inflammation and a decrease in gross pathology 
scores (refer to Table 3). Furthermore, bacterial composition variance is emerging as an important 
factor in overall gut health and the development of gut-associated immune pathologies, with some 
evidence suggesting habitual consumption of health-promoting bacterial species can alter microbial 
populations in the gut, preventing UC.  
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The health benefit of probiotic co-administration with prebiotics has also been explored in the 
context of B. longum, which was found to reduce levels of β-defensins, TNF-α, IL-1α and c-reactive 
protein (CRP) in a synbiotic “mix” [170]. In support, a more recent study conducted on UC patients, 
compared the effects of synbiotics with single probiotic treatment, finding only synbiotic therapy, to 
significantly suppress CRP levels [171]. In addition, CRP has been found to correlate with disease 
severity, implying potential use of CRP levels as a marker of UC progression [195]. Therefore if 
synbiotics act to reduce levels of these pathogenic factors, to an extent greater than probiotics alone, 
further studies must be conducted to explore optimal combinations of probiotics and prebiotics for 
therapeutic use. 
5.2.1. Anti-Tumoural Responses and NK Cell Activation 
Natural killer cells (NKs) play a crucial role in tumour surveillance and anti-viral responses. NKs 
are directly activated by missing or altered self (MHC I), thus responding to suppressive, survival 
mechanisms elicited by viruses and tumour cells. In addition, NKs are indirectly activated by DCs 
which secrete soluble factors, such as IL-12, IL-18 and type I interferons. Priming of NKs 
subsequently leads to killing of tumour cells and the secretion of IFNγ and TNF-α, both  
pro-inflammatory cytokines capable of inducing cell-mediated immunity and further activation of 
antigen-presenting cells (DCs and macrophages) [196] (refer to Figure 1). Interestingly, recent studies 
have highlighted a role for probiotics in modulating the DC-NK interaction and subsequent  
anti-tumour immune responses.  
Probiotic Lactobacillus strains induce human PBMC secretion of pro-inflammatory cytokines,  
IL-12 and TNFα [121]. This has since been identified to be a DC-NK mediated immune response. 
Probiotic Lactobacillus casei Shirota (LcS) induces IL-12 and TNFα production which positively 
correlated to NK activity [125,129]. DC secretion of IL-12 primes NK activation and the subsequent 
secretion of TNF-α, therefore LcS may indirectly activate NK effector function via DCs. This potential 
probiotic mechanism was further proven by studies finding Lactobacillus strains induced APC 
production of IL-12, leading to NK activation and NK-derived IFNγ secretion, which not only has 
implications to innate responses but also CMI-mediated anti-tumour responses [114,132]. 
Lactobacillus-induced IL-12 however, was found to be abrogated in favour of enhanced IL-10 
production, (favouring an immune-suppressive, pro-tumoral environment), by the probiotic, 
Bifidobacterium, suggesting combinatory probiotic therapy may be counter-productive to 
immunomodulation, in the context of NK-mediated immunity [132]. This further highlights a 
generalised distinction between probiotic strains, suggesting Lactobacillus predominantly induces a 
cytotoxic innate immune response (anti-tumour responses) whereas Bifidobacterium play a more 
regulatory role that may involve priming of regulatory T-cells (pro-tumoural responses).  
5.2.2. Colorectal Cancer 
Since the early work of Rudolph Virkchow in the 1800s, evidence has been accumulated supporting 
the hypothesis that chronic inflammation is important in cancer development. As inflammation 
contributes largely to the development and progression of ulcerative colitis (UC), mechanistic links 
have been made between ulcerative colitis and the development of colorectal cancer (CRC).  
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Up-regulation of pro-inflammatory cytokines has been characterised in both UC and CRC [197] and 
development of CRC occurs within the same tissue site as UC; the chronic inflammation and 
subsequent tissue damage observed in UC may therefore be causing CRC. As probiotics and synbiotics 
have both been identified as potentially therapeutic, a similar therapeutic approach could be used  
for CRC.  
Although precise immunomodulatory mechanisms are yet to be clearly defined for probiotics in the 
context of CRC, probiotics have been found to modulate some pro-inflammatory molecules. A recent 
study highlighted L. lactis as capable of decreasing levels of hydrogen peroxide (H2O2) and enhancing 
catalase activity, resulting in decreased colonic damage and tissue inflammation, in a BALB/c mouse 
model [177]. Reactive oxygen species (ROS), such as hydrogen peroxide, are known to contribute to 
carcinogenesis and metastasis as part of the pro-inflammatory immune response, thus suggesting 
probiotics are able to target other inflammatory mediators as well as cytokines. Furthermore,  
L. acidophilus induced a decrease in mRNA expression of stromal-derived factor-1 receptor, CXCR4, 
suggesting a role in cancer metastasis prevention; on the down side however, also suppressed  
MHC-class I expression [180]. As antigen presenting cells (APCs) use MHC-I molecules to present 
antigen to CD8+ Tc, an important component of tumour surveillance, the findings of Chen et al., 
present a potential drawback to the use of L. acidophilus. Activation of CD8+ Tc is desirable within  
the tumour microenvironment due to their anti-tumoural, cytotoxic characteristics; therefore,  
probiotic-mediated down-regulation of CD8+ Tc activation may perpetuate tumour growth and 
survival. In terms of gross pathology, L. acidophilus has been found to decrease tumour growth by 
50% in comparison to non-treated mice and enhance the apoptosis of CT-26 cancer cells [180], 
suggesting the immunomodulatory effects of probiotic administration does have an impact on 
tissue ultrastructure.  
In addition to inhibiting pro-inflammatory mediators, the Lactobacillus mix VSL#3 was found to 
increase angiostatin, the endogenous inhibitor of angiogenesis and regulatory T-cells, in DSS-induced 
CRC mice [179]. In contrast, the study also observed an increase in the number of memory CD4+  
T-cells and pro-inflammatory cytokines, IL-17 and TNFα. As cancer is a complex disease with 
evidence suggesting both pro- and anti-inflammatory mechanisms contributing to cancer progression, 
the varied immunomodulatory roles of probiotics suggests precise strain selection is required for 
accurate targeting of immune function in different pathologies including colorectal cancer. The stage 
of development of colorectal cancer may be the determining factor as to which probiotic strain is used.  
As diet is an important risk factor in susceptibility to CRC, with vitamin D3 and retinoic acid 
inferring positive effects [198] and heterocyclic amines in red meat acting as mutagens [199,200]; 
modulation of the dietary composites within the gastrointestinal tract, suggests scope for intervention 
with prebiotic substrates. As prebiotics are also known to work synergistically with probiotics to elicit 
beneficial effects on commensal populations and overall gut health, synbiotics have been explored as 
potential therapeutic agents in CRC. Studies using bifidobacteria and Lactobacillus strains in 
conjunction with prebiotics, such as inulin and oligofructose, have been found to off-set 
carcinogenesis. Evidence demonstrating inhibition of aberrant crypt formation, reduction of caecal  
pH [175] and increased short chain fatty acid (SCFA) production [176], suggests probiotics could be 
acting through a range of mechanisms. Direct immune modulation has also been found with B. lactis 
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and L. rhamnosus which were shown to decrease IL-2 and inducible NO synthase, the enzyme 
responsible for nitric oxide production [176,178].  
Collectively these studies highlight an important role for probiotics in modulation of  
pro-inflammatory and pro-tumoural immune responses (refer to Table 3). As colorectal cancer can 
arise from untreated colitis, these studies suggest potential use of probiotics as an anti-inflammatory 
therapeutic, utilised not only in pre-established colorectal cancer cases, but also as a preventative 
measure in patients exhibiting symptomatic signs of colitis or early-stage colorectal cancer. 
Furthermore, some experimental evidence suggests an important role for prebiotics, highlighting 
possible functional dependency of probiotics on prebiotic supplementation.  
5.3. Immunopathology: Hypersensitivity 
5.3.1. Allergy & Type I Hypersensitivity 
Dysbiosis in the human gut is not only seen in gastrointestinal tract pathology but is also associated 
with disease at distal sites such as the airways of the lungs [201] and the skin [202,203]. Cross-talk 
between the microbiota and immune cells located in the mucosa and lamina propria not only primes 
and tolerises cells locally, but may initiate migration away from the gut towards the mesenteric lymph 
nodes and other lymphoid tissues inducing systemic immunomodulatory effects [204]. 
Hypersensitivity immune responses are undesirable over-exuberant immune responses mounted to 
an allergic antigen, or allergen. Hypersensitivity responses are categorised in accordance to the time 
taken for an immune response to be mounted and the effector cells and mediators involved. Type-1 
hypersensitivity involves an anaphylactic response rapidly initiated to allergenic exposure. This 
response is predominated by mast cells and basophils, both granulocytes capable of secreting 
vasoactive amines, such as histamines, upon activation of its high-affinity Fc receptors by IgE (refer to 
Figure 1). This type of hypersensitivity also involves Th2 cell-derived mediators such as IL-4, IL-5 
and IL-13, which induce immunoglobulin class switching to IgE. Modulation of this response, via  
T-cell subset skewing (e.g., Th2 to Th1 or enhancement of Treg), is a desirable therapeutic approach to 
allergic pathologies, such as atopic dermatitis and food hypersensitivity, modulatable by 
probiotic administration.  
A number of clinical studies examining differences in microflora between children who displayed 
early symptoms of atopy and healthy controls, showed a higher prevalence of Clostridia and 
Bacteroides but lower comparative numbers of Lactobacilli and bifidobacteria [205,206]. Although 
lactic acid bacteria have been shown to attenuate atopic dermatitis development in mice in a strain 
dependent manner [207,208], there appears to be little significant effect on human infants already 
displaying symptoms [209]. Further investigation in animal studies [210,211] and human clinical  
trials [212,213] has suggested that there may be a window of oportunity in early life before weaning in 
which probiotic therapy is of use in prevention. This positive probiotic effect arises as a consequence 
of immune education to microbes and the establishment of a more balanced immune system in the 
context of Th1, Th17 and Th2 responses. 
Current treatments for allergic diseases such as asthma and food allergy are limited to management 
of the conditions, rather than cure. Probiotic immunomodulation is an attractive strategy with  
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which to counterbalance Th2-skewed immune responses associated with allergy. In vitro studies using 
human peripheral blood mononuclear cells (PBMCs) from allergic patients have shown reduced 
expression of Th2-associated cytokines (IL-4 and IL-5) on stimulation with total extract of 
Dermatophagoides pteronyssinus (house dust mite) and prior treatment with lactic acid bacteria strains 
such as Lactobacillus plantarum [122]. Both Lactococcus lactis and Lactobacillus plantarum, induce 
high levels of IL-12 and IFNγ, suppressing Th2 differentiation [128,181]. In contrast, suppression of 
contact dermatitis in mice has been shown to be mediated by a Lactobacillus acidophilus  
L92-dependent generation of Tregs [214]. This effect is thought to result from strain-dependent 
tolerisation of DCs, increasing suppressor activity of natural Tregs as well as inducing Foxp3+ 
conversion through high expression of IL-10, TGFβ, COX-2 and indoleamine 2,3-dioxygenase [215,216]. 
Several studies, focussing on probiotic administration in type-1 hypersensitivity responses, revealed 
inhibitory characteristics for both Lactobacillus and Bifidobacterium strains. Mouse models have 
demonstrated the ability of L. casei and B. longum to inhibit IgE production [217–219]. Inhibition of 
antibody production prevents binding to Fc receptors on mast cells, thus inhibiting the secretion of 
vasoactive amines, such as histamines, and other inflammatory mediators, such as TNF-α. Indeed, 
histamine content was found to be decreased in Bifidobacterium treated rats [220] and TNF-α 
production was found to be inhibited by another Lactobacillus strain, L. reuteri [144], further 
supporting the role of probiotics in inhibiting mast cell effector function. Systemically, the inhibition 
of mast cell effector function by probiotics has been associated with preventable anaphylaxis [217]. 
The inhibition of IgE production is thought to be a consequence of direct action by probiotics on Th2 
cells or APCs, which prime B-cell activation and class-switching. A large body of evidence 
demonstrates a role for Lactobacillus and Bifidobacterium strains in decreasing the levels of secreted 
IL-4 and IL-5. Both cytokines are Th2-derived, with IL-4 acting on B-cells to induce class-switching 
and on mast cells to induce degranulation and further cytokine production, and IL-5 inducing 
eosinophil degranulation. Specific strains found to inhibit IL-4 and IL-5 production include  
L. casei [219], L. rhamnosus [128], B. longum [218] and B. infantis [220]; see Table 1. 
The effects of probiotics on type-I hypersensitivity responses have been further explored by a few 
studies, in terms of modulation of receptor expression and associated intracellular signalling cascades. 
Dev et al. [220] found the probiotic mix (LacB) composed of B. longum and B. infantis, inhibited the 
increase in histamine receptor-1 and histidine decarboxylase (HDC) expression and activity. 
Furthermore, histamine-2, known to inhibit hypersensitivity responses through activation of cAMP and 
increased intracellular calcium levels, was augmented by L. reuteri [144]. In addition, L. casei 
treatment in mice inhibited IgE production by inhibition of Syk/Lyn and MAPK signalling [219]. This 
provides some insight into probiotic targeting; suggesting probiotics mediate their anti-hypersensitivity 
effects through direct modulation of APC intracellular signalling with knock-on effects to  
down-stream effector cell priming. Unlike other probiotic immunomodulatory effects, there seems to 
be a commonality across probiotic strains in relation to its impact on hypersensitivity responses; 
whether the strain is Lactobacillus or Bifidobacterium derived, the immune response is shifted from a 
predominant Th2 response. Probiotics therefore may have a useful application in Th2-dominant 
pathologies whereby unnecessary immune responses are mounted against self or non-pathogenic 
antigens, such as atopic dermatitis or allergy. 
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Discrepancies have been seen in experiments testing the effectiveness of synbiotic mixtures. 
Bifidobacterium breve and oligosaccharide treatment used in a cohort of 29 patients with asthma, 
found a decrease in IL-5, IL-4 and IL-13 [182], yet the same synbiotic mix tested in atopic dermatitis 
infants found no significant difference in IL-5 levels. Furthermore, in response to allergen-specific 
stimuli, decreases in IL-12 production were found in conjunction with unchanging levels of Tregs [183]. 
Previously, an extensive study in a cohort of 90 infants, receiving the same synbiotic treatment, 
showed an increase in the number of faecal bifidobacteria and a decrease in the number of Clostridium 
colonies accompanied by a decrease in faecal pH; no significant changes were found in levels of IgE 
or the SCFA, acetic acid [184]. This study however did permit the use of topical corticosteroids during 
the experiment; a confounding variable that could have altered the effects of synbiotics on immune 
modulation. Thus, probiotics and synbiotics represent an efficacious approach to the control of 
hypersensitivity/allergy (refer to Table 3). There is a need to characterise immune hypersensitivity 
reactions and their modulation by these pro- and syn-biotics, as future use of these in the treatment of 
allergy will require an appreciation for strain variations in determining immune suppression  
or immune-deviation. The requirement for which will vary according to specific allergens  
and hypersensitivity. 
5.3.2. Coeliac Disease 
At the other extreme of allergic responses is delayed type hypersensitivity (DTH) which includes 
the condition Coeliac disease, although this pathology encompasses many aspects of hypersensitivity 
reactions which culminate in an autoimmune-like disorder. This disease is associated with the gut 
mucosa triggered by an inappropriate immune response to the dietary antigen gluten (α-gliadin), more 
specifically toxic peptide elements resistant to proteolytic breakdown, in individuals who express the 
(HLA-DQ2/DQ8) antigen presenting molecule [187,221]. In this way, gliadin-derived peptides are 
presented to naïve and Th1 cells inducing secretion of IFNγ; additionally, gliadin-derived peptides  
(α-gliadin p31-43/49) induce high-level expression of membrane-bound IL-15 on intestinal epithelial 
cells inducing infiltration of intraepithelial lymphocytes [222–224]. IL-15 induces the expression of 
MICA by physiologically stressed intestinal epithelial cells, promoting the infiltration of NK cells and 
intraepithelial lymphocytes expressing the NKG2D receptor, resulting in the lysis of epithelial  
cells and the breakdown of the mucosal barrier, hence villous atrophy characteristic of coeliac  
disease [224–227] (refer to Figure 1). It has been shown that high levels of TNFα and IL-18, with 
surprisingly little IL-12, exist in people with this Th1-biased condition; IL18 drives the transcription 
factor T bet and thus induces naïve T helper cell differentiation towards Th1 [228]. The mechanisms 
underpinning this complex hypersensitivity type IV-predominated pathology are further complexed by 
the observations that antibodies play a role in this pathology; sIgA facilitates trancytosis of gliadin 
peptides across the epithelial barrier and autoantibodies (IgA and IgG) recognising tissue 
transglutaminase, normally involved in the breakdown of gliadin at the epithelial apical  
surface [229–231]. 
Coeliac patients have a dysbiosis in their gut microflora with lower variation in beneficial 
commensal strains of Bifidobacterium and the atypical expression of Leuconostoc mesenteroides and 
L. carnosum along with Lactobacllius curvatus, believed to be characteristic of coeliac  
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patients [232,233]. The strain Bifidobacterium longum was significantly lower in coeliac patients than 
controls, whereas B. bifidum was higher in those with active disease [233]. Thus, a recent study looked 
at the effects of various bacterial strains isolated from coeliac patients on co-cultures of Caco-2 cells 
and PBMCs in the presence of the antigen gliadin and cytokine trigger IFNγ, then examined for 
cytokine release [187]. The bacterium Shigella CBD8 was found to induce higher secretion of IL-12 
and IFNγ in the presence of gliadin than stimulation with antigen alone, whereas stimulation with the 
strains Bifidobacterium bifidum induced higher levels of TNF-α than the other bacterial strains [187]. 
Thus strains present in the coeliac gut could either reduce disease risk or enhance the proinflammatory 
response to gliadin, and that the high levels of gram negative bacteria with fewer bifidobacteria than 
healthy individuals could be partially responsible for the disease pathogenesis [187]. To this end, the 
live strains of Bifidobacterium lactis and Lactobacillus fermentum were co-cultured with Caco-2 cells 
exposed to gliadin to monitor changes in transepithelial resistance; results demonstrated that B. lactis 
counteracted the effects of gliadin on TER, whereas L. fermentum had no effect at preventing 
increased permeability [186]. A recent review by Silano et al., [234] discusses the fact that there 
appears to be a similar timing mechanism involved in the development of coeliac disease as is seen for 
nut allergy. There would appear to be a time-period in infancy where the risks associated with gluten 
intolerance can be minimised during weaning, the risk is increased before 3 months of age and after  
7 months of age, it is also known that breast-feeding during the weaning period onto gluten halves the 
risk of developing coeliac disease. 
Due to the variable immunological nature of coeliac disease, the use of probiotics is rather  
complex and associated impacts are hard to monitor experimentally (refer to Table 3). Studies using 
gliadin-immunised human HLA-DQ8 transgenic mice, found that two different strains of probiotic 
Lactobacillus paracasei and Lactobacillus fermentum increased the levels of antigen-specific TNF-α, 
and Lactobacillus casei induced a strong increase in CD4+ T cell population and IFNγ  
secretion [185,188]. However, it was later discovered that the administration of this L.casei in a 
murine NSAID-induced intestinal injury model, again expressing the HLA-DQ8 transgene, in fact had 
a preventative effect on villous atrophy, yet this effect was only mediated with prolonged use of the 
probiotic [235]. The literature available regarding the use of prebiotics as a therapy in this pathology is 
scarce. The accepted treatment for coeliac disease however, involves avoidance of dietary gluten and 
the use of inulin in gluten-free bread is being introduced as a method for producing wheat replacement 
foods with an improved consistency in order to help individuals adhere to the strict dietary  
regime [236]. Such use of the prebiotic, inulin, is likely to have an effect on the gut microbiota, 
potentially redressing the dysbiosis observed with this hypersensitivity-associated pathology. 
6. Future Perspectives 
This review has gone some way in highlighting the complexity of mechanistic effects elicited by 
the use of probiotics in the modulation of the human immune system. In the context of homeostatic gut 
mucosa and microbiota, the use of probiotics and indeed combination with prebiotics acts as a regimen 
for long health. In the case of gut pathology, whether inflammatory bowel disease, colorectal cancer or 
hypersensitivity, the use of prebiotics and probiotics in combination can have dramatic effects on the 
immune system, hence immunopathology. Future developments will only surface upon more extensive 
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research into the mechanism underpinning these immunopathologies and how they may be modulated 
by prebiotics, probiotics and synbiotics. There are many areas of interest that can be mentioned;  
some which may be considered however, include (i) the role of pre-/probiotic modulators in 
immunosenescence, (ii) modulation of APC function, in particular mucosal macrophages, (iii) probiotic 
bacterial products (cell wall-associated and secreted) and finally, (iv) faecal transplantation. 
Immunoscenescence: it is well established that the immune system deteriorates with old age. This 
includes thymic atrophy, hence reduction in overall T cell responses and a reduction in numbers and 
activity of NK cells [237,238]. Both these compartments of the immune system are vital to tumour 
surveillance; a reduction in which increases the prevalence of cancer in old age. Studies are surfacing 
which are focussing in on the ability of probiotics to augment the activity of DCs, NK cells and  
CD8+ Tc with some impressive results; responses not otherwise observed in healthy, younger 
populations [129,239]. 
Mucosal macrophages: represent an important APC, which remain resident in the responding tissue, 
as such are able to directly modulate local T cell, B cell, NK, DC, IEL and mast cell responses. There 
is an established literature for macrophage effector subsets, where type I macrophages are  
pro-inflammatory and type II are anti-inflammatory/regulatory. Manipulation of macrophage plasticity 
through probiotics, their secreted products and prebiotics, hold potential for harnessing their 
differential effector responses in the treatment of gut mucosal inflammatory bowel diseases, gut cancer 
and hypersensitivity (reviewed in [138]). 
Probiotic bacterial products: probiotic bacteria may exert their immune-modulatory activity either 
by direct interaction of the bacterial cell with host immune cells or via secretable products. With the 
vast proliferation of the pattern recognition receptor literature, interest is growing with respect to 
characterising the commensal-associated molecular patterns (CAMPs). These patterns are already 
being described for their immunomodulatory functionality and include cell wall components such as 
Lactobacillus plantarum lipoteichoic acid, which exhibits anti-inflammatory effects [240,241] and  
C-type lectins, which interact with DC-SIGN on DCs, resulting in the induction of Tregs [115]. 
Finally, the characterisation of the lactobacillus, exoproteosome, is likely to introduce many secretable 
immunomodulatory molecules (reviewed in [242]). 
Faecal transplantation: It is generally considered that the GIT microbiota of healthy adults remains 
in a stable state of eubiosis. However as work continues on probiotic research, it is increasingly 
apparent that factors such as mode of delivery and feeding regimen in early life in conjunction with 
host genetics, antibiotic usage and life style, influence the composition of the microbiota making it 
genetically and metabolically unique to the individual [243]. The extent of this variation is likely to be 
the primary source of inconclusive results from clinical trials testing prebiotic/probiotic/symbiotic 
formulations in humans, as one person’s microbial balance may not suit another. Yatsunenko et al., [244], 
revealed that GIT microbial composition is most alike between cohabiting individuals compared to 
those from other families. This similarity may provide a unique resource for rebooting the GIT 
microbiota resulting in alleviation of disease associated with microbial dysbiosis. Allogenic faecal 
transplantation has been successfully used in the resolution of C. difficile infections [245] and presents 
promise for the management of symptoms in IBD patients [245]. Furthermore, faecal transplantation 
may provide a strategy to prevent or treat inappropriate immune responses at sites distal to the GIT, 
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such as those seen in asthma and allergic rhinitis, through Th1-mediated cross-regulation of Th2 
responses and generation of Tregs, which may suppress effector T cells mobilised in allergy.  
7. Conclusions 
In addition to playing an important role in barrier defence, probiotics have an ever-unfolding role to 
play in the modulation of mucosal immunity. Probiotic bacteria can modulate the activity of many 
cells of the immune system, including innate system NKs, DCs, macrophages, epithelial cells and 
granulocytes, as well as adaptive system Th1, Th2, Th17, Treg, Tc and B cells. Thus, probiotic 
bacteria have the potential to modulate any part of the immune system in the context of acute 
responses to intracellular or extracellular pathogens or chronic responses observed in dysregulated 
immunopathological conditions such as IBD, colorectal cancer and hypersensitivity. Modulation of 
immunopathology to the advantage of the human host can only realistically occur upon a full 
knowledge of the modulatory capabilities of the probiotic and a full appreciation of the mechanisms 
underpinning the pathology. Probiotic bacterial strains can be generalised to exert immune-activation,  
-deviation or -regulation/suppression responses. Thus, selection of probiotic strains, and indeed 
combinations of probiotics, will be formulated upon careful consideration of the disease mechanisms 
and the desired immunomodulatory effect. Finally, the growing body of evidence for the suitability  
of prebiotics in immunomodulation and formulation with probiotic strains, as synbiotics,  
represents a realistic approach in disease modification. The probiotic species acting as a quick-fix 
immunomodulatory “plaster” and the prebiotic facilitating commensal organisms, modulating the 
dysbiosis in the gut microbiota and further modifying the immune system to our benefit—healing  
from within!! 
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